Deutsche Bank
VBIV

Deutsche Bank’s VBI Vaccines, Inc. New Common Stock (Canada) VBIV Stock Holding History

Deutsche Bank’s Portfolio VBIV Stock Details VBIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-5,928
Closed -$19.5K – 3856
2023
Q2 		$19.5K Buy
5,928
+515
+10% +$1.56K ﹤0.01% 3584
2023
Q1 		$49.2K Sell
5,413
-3,916
-42% -$55.5K ﹤0.01% 3551
2022
Q4 		$109K Buy
9,329
+2,306
+33% +$40.7K ﹤0.01% 3292
2022
Q3 		$149K Sell
7,023
-23
-0.3% -$620 ﹤0.01% 3124
2022
Q2 		$171K Buy
7,046
+899
+15% +$30.6K ﹤0.01% 3258
2022
Q1 		$306K Buy
6,147
+1,648
+37% +$81.4K ﹤0.01% 3034
2021
Q4 		$316K Buy
4,499
+140
+3% +$11.8K ﹤0.01% 3115
2021
Q3 		$407K Sell
4,359
-170
-4% -$16.2K ﹤0.01% 3176
2021
Q2 		$456K Sell
4,529
-12
-0.3% -$1.17K ﹤0.01% 3280
2021
Q1 		$424K Sell
4,541
-365
-7% -$37K ﹤0.01% 3209
2020
Q4 		$405K Buy
4,906
+1,790
+57% +$153K ﹤0.01% 3048
2020
Q3 		$268K Buy
3,116
+277
+10% +$32.3K ﹤0.01% 3045
2020
Q2 		$264K Buy
2,839
+1,028
+57% +$56.6K ﹤0.01% 2999
2020
Q1 		$52K Sell
1,811
-91
-5% -$3.54K ﹤0.01% 3534
2019
Q4 		$77K Buy
1,902
+1,119
+143% +$24.5K ﹤0.01% 3715
2019
Q3 		$9K Sell
783
-1,343
-63% -$28.1K ﹤0.01% 4543
2019
Q2 		$72K Buy
+2,126
New +$115K ﹤0.01% 4358
2018
Q4 		– Sell
-2,140
Closed -$155K – 5474
2018
Q3 		$155K Buy
2,140
+1,244
+139% +$82K ﹤0.01% 4342
2018
Q2 		$74K Sell
896
-711
-44% -$68.7K ﹤0.01% 4649
2018
Q1 		$168K Sell
1,607
-3,968
-71% -$474K ﹤0.01% 4281
2017
Q4 		$713K Buy
5,575
+4,930
+764% +$606K ﹤0.01% 3428
2017
Q3 		$73K Sell
645
-185
-22% -$22.2K ﹤0.01% 4268
2017
Q2 		$106K Buy
+830
New +$112K ﹤0.01% 4186
2017
Q1 		– Sell
-192
Closed -$17K – 5140
2016
Q4 		$17K Buy
192
+176
+1,100% +$16.8K ﹤0.01% 4629
2016
Q3 		$1K Buy
+16
New +$1.79K ﹤0.01% 4861

Other funds holding VBIV

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GAI
General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Deutsche Bank's VBIV Position: Q3 2023 in Review

Deutsche Bank sold out of VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) in Q3 2023, closing a stake of 5,928 shares — an estimated $19.5K sold.

Deutsche Bank first reported a position in VBIV in Q3 2016 and held it in 25 quarters. The position peaked at $713K in Q4 2017. 37 funds tracked by Wall St. Rank hold VBIV as of Q3 2023.

  • Deutsche Bank reported no remaining VBI Vaccines, Inc. New Common Stock (Canada) position as of Q3 2023 after selling out during the quarter.
  • Deutsche Bank sold 5,928 VBI Vaccines, Inc. New Common Stock (Canada) shares in Q3 2023, an estimated $19.5K.
  • Deutsche Bank first reported a position in VBI Vaccines, Inc. New Common Stock (Canada) in Q3 2016 and held it in 25 quarters.
  • Deutsche Bank's VBI Vaccines, Inc. New Common Stock (Canada) position peaked at $713K in Q4 2017.
  • 37 funds tracked by Wall St. Rank held VBI Vaccines, Inc. New Common Stock (Canada) as of Q3 2023.

Based on Deutsche Bank's 13F filing for Q3 2023, filed 9 Nov 2023.